Jaguar Health, Inc. (JAGX) Form 8-K — Nov 16, 2026
Jaguar Health reported Q3 2026 total net revenue of $2.34 million, down 24% year over year, as prescription product revenue fell 81.9% to $551K following the January 2026 licensing of Mytesi and Canalevia-CA1 U.S. commercial rights to Future Pak. Net loss improved 39.6% to $5.83 million from $9.65 million a year ago, and non-GAAP recurring EBITDA loss narrowed to $5.0 million from $9.0 million, helped by the dissolution of the salesforce and roughly $2.0 million lower operating expenses under the Future Pak deal.
Key figures
- Revenue
- 2343000
- Guidance
- Planned NDA filing for crofelemer for MVID in mid-2027
- Revenue Yoy
- -24.0%
- Deferred revenue
- $425,000
- Holdback received
- ~$1.8 million
- Loss from operations
- -$6.023M (vs -$7.238M, +16.8% improvement)
- Debt reduction q3 2026
- $10.1 million
- Future pak upfront payment
- $16 million (recognized Q1 2026)
- Non gaaap recurring ebitda
- -$5.032M (vs -$9.025M)
- Gain on debt extinguishment
- $0.558M (Streeterville New Note)
- Product revenue net q3 2026
- $551K (vs $3.04M Q3 2025, -81.9%)
- License and grant revenue q3 2026
- $1.792M (vs $42K Q3 2025)
- Buy back option termination payment
- $3 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.